Traverso Chambers Private Wealth Management’s Myriad Genetics MYGN Stock Holding History

Traverso Chambers Private Wealth Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,357	Closed	-$166K	–	124
2023 Q3	$166K	Hold	10,357	–	–	0.04%	113
2023 Q2	$240K	Hold	10,357	–	–	0.06%	104
2023 Q1	$241K	Hold	10,357	–	–	0.07%	103
2022 Q4	$150K	Hold	10,357	–	–	0.04%	107
2022 Q3	$198K	Hold	10,357	–	–	0.06%	109
2022 Q2	$188K	Hold	10,357	–	–	0.06%	104
2022 Q1	$261K	Hold	10,357	–	–	0.08%	103
2021 Q4	$286K	Hold	10,357	–	–	0.08%	97
2021 Q3	$334K	Hold	10,357	–	–	0.1%	89
2021 Q2	$317K	Hold	10,357	–	–	0.1%	91
2021 Q1	$315K	Sell	10,357 -6,500	-39%	-$184K	0.11%	83
2020 Q4	$333K	Hold	16,857	–	–	0.12%	79
2020 Q3	$220K	Hold	16,857	–	–	0.09%	95
2020 Q2	$191K	Hold	16,857	–	–	0.08%	95
2020 Q1	$241K	Buy	16,857 +5,000	+42%	+$106K	0.11%	81
2019 Q4	$323K	Buy	+11,857	New	+$326K	0.14%	77

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Traverso Chambers Private Wealth Management's MYGN Position: Q4 2023 in Review

Traverso Chambers Private Wealth Management sold out of Myriad Genetics (MYGN) in Q4 2023, closing a stake of 10,357 shares — an estimated $166K sold.

Traverso Chambers Private Wealth Management first reported a position in MYGN in Q4 2019 and held it in 16 quarters. The position peaked at $334K in Q3 2021. 194 funds tracked by Wall St. Rank hold MYGN as of Q4 2023.

Traverso Chambers Private Wealth Management reported no remaining Myriad Genetics position as of Q4 2023 after selling out during the quarter.
Traverso Chambers Private Wealth Management sold 10,357 Myriad Genetics shares in Q4 2023, an estimated $166K.
Traverso Chambers Private Wealth Management first reported a position in Myriad Genetics in Q4 2019 and held it in 16 quarters.
Traverso Chambers Private Wealth Management's Myriad Genetics position peaked at $334K in Q3 2021.
194 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2023.

Based on Traverso Chambers Private Wealth Management's 13F filing for Q4 2023, filed 9 Jan 2024.